Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
latest_posts
- 1
Instructions to Perform Fundamental Upkeep on Your Slam 1500. - 2Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- 3Equality requires universal draft, participation in economy and workforce, MK Liberman says
- 4Was This Driver Simply Having A great time Or Behaving Like An Ass?
- 57 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- The Best 20 Tunes that Characterized an Age
- Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- Strengthening through Wellness: Individual Preparation Achievement
- The 20 Most sultry Style of the Time
- I thought I knew the night sky, but what I saw from the Canary Islands left me speechless
- 6 Monetary Arranging Administrations for Your Necessities
- Which Breakfast Enraptures Your Taste Buds? Vote
- Step by step instructions to Protect Your Retirement with Senior Protection.
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
